Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapyJeremy S. Abramson, Andrew M. Evens, Frederick Lansigan et al.|Annals of Oncology|2014Cited by 138
Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical PracticeLindsey E. Roeker, Anthony R. Mato, Christopher P. Fox et al.|Clinical Cancer Research|2019Cited by 90
Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimenMeghan C. Thompson, Anthony R. Mato, Rosemary Harrup et al.|Blood Advances|2022Cited by 57